Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 8:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 4,108 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Experimental 2 Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical Evaluation of a Reusable Multifocal Optical Design in a Presbyopic Population

NCT03581825
View directory record Official record
Conditions
Visual Acuity
Interventions
senofilcon A Multifocal, senofilcon A Sphere, etafilcon A Multifocal, etafilcon A Sphere
Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
40 Years to 70 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
6
States / cities
Orlando, Florida • East Lansing, Michigan • Raytown, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated May 8, 2020 · Synced Oct 31, 2026, 8:30 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of the Safety and Immunogenicity of an Influenza Vaccine Administered to Healthy Adults

NCT00264576
View directory record Official record
Conditions
Influenza Disease; Flu
Interventions
Influenza Virus Vaccine
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
18 Years to 49 Years
Enrollment
613 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
4
States / cities
Bardstown, Kentucky • Pittsburgh, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 31, 2026, 8:30 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC

NCT05191017
View directory record Official record
Conditions
Prostate Cancer, Prostatic Cancer, Cancer of Prostate, Cancer of the Prostate, Prostate Neoplasm, Castrate Resistant Prostate Cancer, Castration Resistant Prostatic Cancer, Castration Resistant Prostatic Neoplasms
Interventions
NUV-422, Enzalutamide
Drug
Lead sponsor
Nuvation Bio Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Canton, Ohio • Gettysburg, Pennsylvania • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 5, 2022 · Synced Oct 31, 2026, 8:30 AM EDT
Completed Phase 3 Interventional Results available

A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies

NCT02594124
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
nusinersen
Drug
Lead sponsor
Biogen
Industry
Eligibility
Not listed
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
18
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Oct 31, 2026, 8:30 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age

NCT05084508
View directory record Official record
Conditions
Chickenpox
Interventions
Investigational varicella vaccine low potency, Investigational varicella vaccine medium potency, Investigational varicella vaccine high potency, Licensed varicella vaccine Lot 1, Licensed varicella vaccine Lot 2, Measles, mumps, and rubella vaccine, Hepatitis A vaccine, 13-valent pneumococcal conjugate vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
41
States / cities
Bryant, Arkansas • Jonesboro, Arkansas • Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 31, 2026, 8:30 AM EDT
Recruiting Not applicable Interventional

Cereset Research Exploratory Study

NCT03777267
View directory record Official record
Conditions
Neurological Diseases or Conditions, Cardiovascular Conditions After Birth, Psychophysiologic Disorders
Interventions
Active CR
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
11 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 31, 2026, 8:30 AM EDT
Terminated Phase 2 Interventional

Initial Pain Management in Pediatric Pancreatitis: Opioid vs. Non-Opioid

NCT04291599
View directory record Official record
Conditions
Acute Pancreatitis
Interventions
Ketorolac, Opioid
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 21 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 31, 2026, 8:30 AM EDT
Terminated Phase 1Phase 2 Interventional

Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma

NCT06516887
View directory record Official record
Conditions
Advanced Lung Adenocarcinoma
Interventions
bemcentinib, pacritinib
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 31, 2026, 8:30 AM EDT
Completed Not applicable Interventional Results available

Evaluation of the Lung Nodule Sensitivity of Stationary Chest Tomosynthesis in Patients With Known Lung Nodules

NCT02075320
View directory record Official record
Conditions
Signs and Symptoms
Interventions
Stationary Digital Chest Tomosynthesis
Device
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Oct 31, 2026, 8:30 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Treatment of Clogged Tympanostomy Tubes: An Off-Label Use of Dornase Alfa (Pulmozyme®)

NCT00419380
View directory record Official record
Conditions
Otitis Media
Interventions
dornase alfa (Pulmozyme®)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
1 Year to 18 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 31, 2026, 8:30 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Cognizin Citicoline Dosing in a Healthy Adolescent Male Population

NCT01582113
View directory record Official record
Conditions
Neurocognitive Improvement
Interventions
Citicoline, Microcrystalline Cellulose
Drug · Other
Lead sponsor
Deborah Yurgelun-Todd
Other
Eligibility
13 Years to 18 Years · Male only
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Oct 31, 2026, 8:30 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer.

NCT04896320
View directory record Official record
Conditions
Breast Cancer Stage IV
Interventions
Tucatinib
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Clackamas, Oregon • Newberg, Oregon • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 31, 2026, 8:30 AM EDT
Not listed Not applicable Interventional

A Comparison of Two Target Mean Arterial Pressures in the Resuscitation of Hypotensive Trauma Patients

NCT00459160
View directory record Official record
Conditions
Hemorrhagic Shock, Trauma, Wounds, Penetrating, Shock, Traumatic, Multiple Trauma
Interventions
Intraoperative Hypotensive Resuscitation
Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years to 45 Years
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 1, 2010 · Synced Oct 31, 2026, 8:30 AM EDT
Completed Phase 2 Interventional Results available

A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease

NCT02431468
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Bryostatin 1, Placebo
Drug · Other
Lead sponsor
Neurotrope Bioscience, Inc.
Industry
Eligibility
55 Years to 85 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
29
States / cities
Phoenix, Arizona • Costa Mesa, California • Los Alamitos, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2018 · Synced Oct 31, 2026, 8:30 AM EDT
Completed Not applicable Interventional Results available

Clinical Biocompatibility Evaluation of Contact Lens Coatings

NCT03034928
View directory record Official record
Conditions
Refractive Errors, Ametropia
Interventions
Contact lens with investigational coating 1, Balafilcon A contact lens, OPTI-FREE® RepleniSH® MPDS, Contact lens with investigational coating 2
Device
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Johns Creek, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Oct 31, 2026, 8:30 AM EDT
Recruiting Phase 2 Interventional

CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial

NCT06949800
View directory record Official record
Conditions
HSIL, High Grade Squamous Intraepithelial Lesion, HPV-Related Squamous Cell Carcinoma, Anal HSIL
Interventions
EXE-346 Probiotic, Placebo, Usual Care High Resolution Anoscopy (HRA)
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 31, 2026, 8:30 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

NCT05050136
View directory record Official record
Conditions
Primary Biliary Cholangitis, PBC
Interventions
Volixibat, Placebo
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
44
States / cities
Coronado, California • Los Angeles, California • Sacramento, California + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 31, 2026, 8:30 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

NCT01243944
View directory record Official record
Conditions
Polycythemia Vera
Interventions
ruxolitinib tablets, Best Available Therapy (BAT)
Drug · Other
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
28
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Pomona, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Oct 31, 2026, 8:30 AM EDT
Completed Phase 3 Interventional Results available

Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR)

NCT00289198
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
FF, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
8
States / cities
San Diego, California • Baltimore, Maryland • Wheaton, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2018 · Synced Oct 31, 2026, 8:30 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of LIPO-5 and ALVAC-HIV (vCP1452) as Possible HIV Vaccines

NCT00076063
View directory record Official record
Conditions
HIV Infections
Interventions
ALVAC-HIV (vCP1452), LIPO-5
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
11
States / cities
Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 31, 2026, 8:30 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F]GATT-44 for Positron Emission Tomography Imaging of the GABA Transporter-1

NCT07457736
View directory record Official record
Conditions
Healthy Adult Participants
Interventions
[ 18F]GATT-44
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 31, 2026, 8:30 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Improving Dietary Quality Through Animal Source Protein Accessibility in a Low-Resource Setting

NCT07620028
View directory record Official record
Conditions
Nutrition Intervention, Healthy Eating, Diet, Healthy, Hunger, Food Security
Interventions
Nutrition Secure Indianapolis Food Box Intervention, Nutrition Secure Indianapolis Nutrition Education
Other · Behavioral
Lead sponsor
Purdue University
Other
Eligibility
5 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 31, 2026, 8:30 AM EDT
Completed Phase 2 Interventional

A Pilot Evaluation of an Experimental BLI4600 Formulation for Bowel Preparation in Adult Patients Undergoing Colonoscopy

NCT02376465
View directory record Official record
Conditions
Bowel Preparation for Colonoscopy
Interventions
BLI4600 bowel preparation, PEG based bowel preparation
Drug
Lead sponsor
Braintree Laboratories
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Oct 31, 2026, 8:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK1349572 Drug Interaction Study With Fosamprenavir/Ritonavir

NCT01209065
View directory record Official record
Conditions
Infections, Human Immunodeficiency Virus and Herpesviridae
Interventions
GSK1349572, Fosamprenavir, Ritonavir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 31, 2026, 8:30 AM EDT